Enliven Therapeutics (ELVN) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Enliven Therapeutics (ELVN) over the past year, gaining 125.5% versus a gain of 92.5%. Over five years, ELVN leads with a +179.9% price change compared with -79.9% for MRVI. Enliven Therapeutics is the larger company by market cap ($3.00 billion vs $2.76 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELVN | MRVI |
|---|---|---|
| Share price | $40.98 | $7.44 |
| Market cap | $3.00B | $2.76B |
| 1-day change | +0.86% | +3.19% |
| YTD return | +166.10% | +128.92% |
| 1-year return | +92.48% | +125.45% |
| 5-year return | +179.92% | -79.94% |
| EPS (TTM) | $-1.67 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $185.74M |
| Revenue growth (YoY) | — | -28.34% |
| Net income (latest FY) | $-103.69M | $-130.77M |
| Gross margin | — | 18.30% |
| Operating margin | — | -115.89% |
| Net margin | — | -70.41% |
| 52-week high | $62.32 | $9.42 |
| 52-week low | $14.79 | $2.55 |
| Distance from 52-week high | -34.24% | -21.02% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +79.77% | +5.24% |
| Average volume | 1.14M | 3.33M |
| Shares outstanding | 73.27M | 148.99M |
| Employees | 67 | 415 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed ELVN by 33.0 percentage points over the past year.
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
ELVN vs MRVI FAQ
Which is bigger, Enliven Therapeutics or Maravai LifeSciences?
Enliven Therapeutics (ELVN) is larger, with a market capitalization of $3.00B compared with $2.76B for Maravai LifeSciences (MRVI).
Which stock has performed better over the past year, ELVN or MRVI?
MRVI returned +125.45% over the past 12 months, compared with +92.48% for ELVN (price return, excluding dividends). Past performance does not predict future results.
Are Enliven Therapeutics and Maravai LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.